Detalles de la búsqueda
1.
Proteogenomics of Non-smoking Lung Cancer in East Asia Delineates Molecular Signatures of Pathogenesis and Progression.
Cell
; 182(1): 226-244.e17, 2020 07 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32649875
2.
Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC.
N Engl J Med
; 2024 Jun 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-38924756
3.
Reduced symmetric dimethylation stabilizes vimentin and promotes metastasis in MTAP-deficient lung cancer.
EMBO Rep
; 23(8): e54265, 2022 08 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35766227
4.
Real-world evidence of lorlatinib therapy in Taiwanese patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer.
J Formos Med Assoc
; 2024 Jan 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38195317
5.
Tissue Proteogenomic Landscape Reveals the Role of Uncharacterized SEL1L3 in Progression and Immunotherapy Response in Lung Adenocarcinoma.
J Proteome Res
; 22(4): 1056-1070, 2023 04 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36349894
6.
Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.
N Engl J Med
; 383(10): 931-943, 2020 09 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32469185
7.
Evaluation of combination treatment with DS-1205c, an AXL kinase inhibitor, and osimertinib in metastatic or unresectable EGFR-mutant non-small cell lung cancer: results from a multicenter, open-label phase 1 study.
Invest New Drugs
; 41(2): 306-316, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36892745
8.
A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data.
Future Oncol
; 19(1): 61-75, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36656302
9.
Thoracic radiotherapy may improve the outcome of extensive stage small cell lung carcinoma patients treated with first-line immunotherapy plus chemotherapy.
Anticancer Drugs
; 33(10): e842-e849, 2022 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36206101
10.
Hybrid Pharmacophore- and Structure-Based Virtual Screening Pipeline to Identify Novel EGFR Inhibitors That Suppress Non-Small Cell Lung Cancer Cell Growth.
Int J Mol Sci
; 23(7)2022 Mar 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-35408854
11.
Histological Transformation after Acquired Resistance to the Third-Generation EGFR-TKI in Patients with Advanced EGFR-Mutant Lung Adenocarcinoma.
Medicina (Kaunas)
; 58(7)2022 Jul 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35888627
12.
Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.
N Engl J Med
; 379(21): 2027-2039, 2018 11 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-30280657
13.
The M1/M2 spectrum and plasticity of malignant pleural effusion-macrophage in advanced lung cancer.
Cancer Immunol Immunother
; 70(5): 1435-1450, 2021 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-33175182
14.
Primary Tumor Resection Is Associated with a Better Outcome among Advanced EGFR-Mutant Lung Adenocarcinoma Patients Receiving EGFR-TKI Treatment.
Oncology
; 99(1): 32-40, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-32894845
15.
Real-world efficacy and safety of lorlatinib in treating advanced ALK-positive non-small cell lung cancer patients.
Anticancer Drugs
; 32(10): 1099-1104, 2021 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34232936
16.
Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations.
Int J Clin Oncol
; 26(5): 841-850, 2021 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-33783657
17.
Impact of tumor disappearance ratio on the prognosis of lung adenocarcinoma ≤2 cm in size: A retrospective cohort study.
J Formos Med Assoc
; 120(2): 874-882, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-32891489
18.
Antiplatelet agents and anticoagulants increased the bleeding risk of bedside percutaneous dilational tracheostomy in critically ill patients.
J Formos Med Assoc
; 119(7): 1193-1200, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-31685407
19.
Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan.
J Formos Med Assoc
; 119(12): 1817-1826, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-32094063
20.
ASTRIS: a global real-world study of osimertinib in >3000 patients with EGFR T790M positive non-small-cell lung cancer.
Future Oncol
; 15(26): 3003-3014, 2019 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-31339357